Search

Your search keyword '"Langerød A"' showing total 398 results

Search Constraints

Start Over You searched for: Author "Langerød A" Remove constraint Author: "Langerød A"
398 results on '"Langerød A"'

Search Results

1. Deep learning for automated scoring of immunohistochemically stained tumour tissue sections – Validation across tumour types based on patient outcomes

2. Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer—a prospective national multicentre study (EMIT-1)

3. BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations

4. Are Metastatic Central Lymph Nodes (D3 volume) in right-sided Colon Cancer a Sign of Systemic Disease? A sub-group Analysis of an Ongoing Multicenter Trial

5. Correction: Discovery and validation of breast cancer subtypes

6. Expression of full-length p53 and its isoform Δp53 in breast carcinomas in relation to mutation status and clinical parameters

7. Discovery and validation of breast cancer subtypes

8. Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk

9. Comparing 5-Year Survival Rates Before and After Re-stratification of Stage I–III Right-Sided Colon Cancer Patients by Establishing the Presence/Absence of Occult Tumor Cells and Lymph Node Metastases in the Different Levels of Surgical Dissection

11. Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53

12. Comprehensive multi-omics analysis of breast cancer reveals distinct long-term prognostic subtypes.

14. Complex landscapes of somatic rearrangement in human breast cancer genomes

15. 103P Impact of Prosigna test on treatment decision in lymph node-negative early breast cancer: A prospective multicenter study (EMIT1)

16. Supplementary Figures S1-S5, Tables 1-3 from Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53

17. Supplementary figures from Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice

18. Supplementary Figure 7 from TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance

19. Supplementary Tables from The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer

20. Data from Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice

21. Supplementary Figure 2 from TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance

22. Supplementary Figure 6 from TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance

23. Supplementary Figure 4 from TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance

24. Supplementary Figure 5 from TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance

25. Supplementary Figure 3 from TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance

26. Supplementary Figure 8 from TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance

27. Supplementary Figure Legends from TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance

28. Supplementary Figure 1 from TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance

29. Supplementary Figures S1-S5, Tables 1-3 from Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53

30. Supplementary Figure 6 from TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance

31. Supplementary Figure 8 from TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance

32. Supplementary Tables from The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer

33. Supplementary Figure 5 from TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance

34. Supplementary Figure 4 from TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance

35. Data from Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice

36. Supplementary Figure 2 from TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance

37. Data from The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer

38. Figure S1, Figure S2 from The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer

39. Data from TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance

40. Supplementary Figure 1 from TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance

41. Supplementary Figure 7 from TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance

42. Supplementary Figure 3 from TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance

44. A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns

45. Combined burden and functional impact tests for cancer driver discovery using DriverPower

46. Integrative pathway enrichment analysis of multivariate omics data

47. Pathway and network analysis of more than 2500 whole cancer genomes

48. Divergent mutational processes distinguish hypoxic and normoxic tumours

49. Genomic footprints of activated telomere maintenance mechanisms in cancer

50. Cis-regulatory mutations associate with transcriptional and post-transcriptional deregulation of gene regulatory programs in cancers

Catalog

Books, media, physical & digital resources